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ABSTRACT
A stereospecific HPLC method for the separation of efavirenz (EFZ) enantiomers in bulk drug and formulations was developed
and validated on a normal-phase cellulose derivatized chiral column. The effect of organic modifiers, namely, 2-propanol, ethanol and
trifluoroacetic acid in mobile phase was optimized to obtain the best enantiomeric separation. The retention times of (R)-EFZ and (S)-EFZ
were observed to be 7.5 and 9.2 min, respectively. The calibration curve was found to be linear over the concentration range of 200 - 6210
ng/mL with a determination coefficient (R2) of 0.9999 for the (R)-isomer. The limit of detection (LOD) and limit of quantification (LOQ)
were calculated to be 66 ng/mL and 200 ng/mL, respectively. The proposed method was found to be accurate, precise and suitable for the
separation and quantification of unwanted (R)-EFZ in active pharmaceutical ingredients (API). The analytical results were supported by
statistical parameters. The proposed method could be successfully applied to the enantiomeric purity analysis of EFZ in bulk drug samples
and formulations.
Key words: efavirenz, enantiomeric separation, HPLC, cellulose-based stationary phase, validation

INTRODUCTION
The United States Food and Drug Administration,
European Committee for Proprietary Medicinal Products and
other drug controlling agencies have issued marketing guidelines for optically active pure drugs and hence, the demand
for chiral separations has increased greatly(1,2). Nowadays,
the separation of enantiomers has become an essential and
important step, particularly in pharmaceutical and biological
fields, since some enantiomers of racemic drugs have relatively different pharmacokinetic properties and diverse
pharmacological or toxicological effects(3-5). This is one of
the most vital reasons why the regulatory authorities insist
on the evaluation of the safety and effectiveness of drugs
containing chiral centers. Enantiomeric separations have
acquired importance in all the stages of drug development
and the commercialization process. Therefore, the development of new methods for efficient chiral separations based on
HPLC, capillary electrophoresis (CE) or gas chromatography
(GC) assume importance.
Efavirenz (EFZ), administered as a single enantiomer,
* Author for correspondence. Tel: +91-836- 2215286/27;
Fax: +91-836-2747884; Email: jseetharam@yahoo.com
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(S)-6-chloro-4-(cyclopropylethynyl)-l,4-dihydro-4(trifluoromethyl)-2H-3,l-benzoxazin-2-one (Figure 1), is
a specific, non-nucleoside reverse transcriptase inhibitor
(NNRTI) of the human immunodeficiency virus type 1
(HIV-1)(6). Its long half-life allows once-daily dosing, and
therefore presents an advantage for treatment compliance
and efficacy(7-9). EFZ undergoes extensive metabolism,
mainly by the cytochrome P-450 isoenzyme, CYP2B6, which
is known to exhibit extensive inter-individual variability.
This could lead to heterogeneity in response to treatment.
A number of high performance liquid chromatographic
methods have been reported for the assay of EFZ in plasma
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Figure 1. Structure of (S)-EFZ.
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alone(10-15) and in combination with other antiviral agents(1628)
. Critical literature survey showed that no chiral HPLC
method has been reported for the separation of the enantiomers of EFZ. In this study, a simple and efficient chiral
HPLC was developed and validated for the separation of
enantiomers of EFZ with commercially available chiral
stationary phase (Chiralcel OD-H). The developed method is
successfully applied for the evaluation of enantiomeric purity
in bulk and pharmaceutical formulations. Further, the method
is sensitive as evident from the low detection limit of 65 ng/
mL for (R)-EFZ.

MATERIALS AND METHODS
I. Chemicals and Reagents
The racemic mixture of EFZ was obtained from
Arobindo Pharmaceuticals (Hyderabad, India). (R)-EFZ
(chemical purity:99.85%; chiral purity:99.51%) and (S)-EFZ
(chemical purity:99.89%; chiral purity:99.91%) were
obtained by purifying the racemic mixture and bulk drug,
respectively, on preparative HPLC. EFZ tablets (Sustiva
600 mg film-coated tablets) were obtained commercially.
N-Hexane (HPLC grade) was purchased from Spectrochem
Pvt. Ltd. (Mumbai, India). 2-propanol was purchased from
Merck (Mumbai, India). Ethanol (absolute) was obtained
from Tedia Company Inc. (Fairfield, OH, USA). Trifluoroacetic acid was purchased from Aldrich Chemicals Co., Inc.
(Milwaukee, WI, USA).
II. Instrumentation
The equipment consisted of a Waters 2695 separation
module system consisting of an online degasser, quaternary
pump, auto-sampler equipped with cooling system, thermostat column compartment and 2996 module PDA (photo
diode array) detector (Waters Corp., Milford, MA, USA).
The output signal was monitored and integrated using Waters
Empower software (Build 1154). The Chiralcel OD-H column
(250 mm × 4.6 mm, 5.0 µm) (Diacel Chemical Industries,
Tokyo, Japan) was used in the study. For method development, Chiralpak AD, AD-H and AD-RH, Chiralcel OD,
OD-H and OD-RH, Chiralcel OJ and OB columns were used
(Diacel Chemical Industries Tokyo, Japan). The mobile phase
and sample/standard preparations were degassed by using a
sonicator (S.V. Scientific, India).
A preparative HPLC system consisting of an Agilent
1200 series (CA, USA) binary pump, auto sampler, PDA
detector and fraction collector was used for obtaining the
standards of (R)-Efavirenz and (S)-Efavirenz using a semipreparative Chiralcel-OD column (250 mm × 10 mm, 10.0
µm) (Diacel Chemical Industries, Tokyo, Japan).
III. Chromatographic Conditions
The mobile phase was prepared by mixing n-hexane,
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2-propanol and trifluoroacetic acid in the ratio of 90 : 10 :
0.05 (v/v/v) and degassed using a vacuum degasser before
use. The flow rate was set at 0.8 mL/min and the column was
maintained at ambient temperature. The injection volume was
10 µL and the detector wavelength was tuned at 245 nm. An
n-hexane and 2-propanol mixture in the ratio of 90 : 10 (v/v)
was used as diluent for sample and standard preparation and
the same was injected as blank. The mobile phase and sample/
standard preparations were degassed using a sonicator.
The column was flushed with a mixture of n-hexane and
2-propanol (90 : 10, v/v) at the end of each day at a flow rate
of 0.4 mL/min for 2 h in order to regenerate after using the
mobile phase containing TFA.
For preparative HPLC, a mobile phase consisting of a
mixture of n-hexane, 2-propanol and trifluoroacetic acid in
the ratio of 90 : 10 : 0.05% (v/v/v) was pumped at a flow rate
of 3.0 mL/min on a semi-preparative Chiralcel-OD (250 mm
× 10 mm) column at ambient temperature. A 1-mL aliquot
of a 15 mg/mL solution of the racemic mixture of EFZ was
injected and the eluent was monitored at 245 nm.
IV. Procedures
(I) Sample Preparation
Bulk drug: 20 mg of the bulk drug EFZ sample was
weighed into a 10-mL volumetric flask. 2 mL of 2-propanol
was added to dissolve the bulk drug with sonication. The
volume was made up to the mark with the diluent and the
solution was filtered through a 0.2-µm syringe filter.
Tablets: Five tablets of EFZ were pulverized and
weighed. The powder equivalent to 10 mg of EFZ was
weighed and transferred into a 10-mL volumetric flask. 2
mL of 2-propanol was added and the mixture was sonicated
for 15 min. 3 mL of diluent was added and the mixture was
sonicated for a further 10 min. The volume was finally made
up to the mark with the diluent and the solution was filtered
through a 0.2-µm syringe filter. It was further diluted as
required for analysis.
(II) Specificity
The specificity of the method was established through
a study of the resolution factors of the enantiomer peaks
from the nearest resolving peak and also among all the other
peaks due to excipients, impurities and degraded products(29).
System suitability parameters were calculated.
(III) Limits of Detection (LOD) and Quantification (LOQ)
The limits of detection and quantitation of EFZ enantiomers were estimated by obtaining the detector signals for
the peaks and by performing serial dilution of a solution of
known concentration. The values of LOD and LOQ were
determined at a signal to noise ratio of 3 : 1 and 10 : 1, respectively. The LOQ value was determined by injecting a series
of test solutions of known concentrations within the linearity
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range. Precision study was also carried out at the LOQ level
by injecting six preparations.
(IV) Precision
The repeatability of the method was evaluated by
calculating the RSD of the area of the unwanted (R)-EFZ in
spiked samples for six replicate injections. Further, the RSD
values were calculated by carrying out the analysis on three
consecutive days, six times in each day.

between 2 - 8°C in a refrigerator and the other on the bench
top in tightly capped volumetric flasks. The stored solutions
of each isomer were analyzed up to 24 h with an interval of
every 6 h.
The mobile phase stability was carried out by evaluating
the content of (R)-EFZ in EFZ sample solutions spiked with
(R)-EFZ at different levels, prepared freshly at 6 h intervals
for 24 h. The same mobile phase was used during the study.
The percentage RSD values were calculated for the mobile
phase and solution stability experiments.

(V) Linearity and Range

RESULTS AND DISCUSSION
The test solutions were prepared from the stock solution
of EFZ so as to contain the drug in the range of 200 - 6210 ng/
mL. The solutions were injected in triplicate into the HPLC
column, using a constant injection volume of 10 µL and the
chromatograms were recorded. The standard drug was spiked
with (R)-EFZ at different concentrations and injected in triplicate. The peak area versus concentration data was treated by
least-squares linear regression analysis. Chromatograms of
the above test solutions were recorded for three consecutive
days in the same concentration range. The percentage RSD
values were calculated.
(VI) Accuracy
The accuracy of the method was evaluated by spiking the
standard drug with known amounts of the unwanted (R)-EFZ
at LOQ level, 0.8, 1.0 and 1.2% of analyte concentration in
triplicate. The recoveries were calculated from the slope and
the intercept obtained for the calibration curve of the (R)-EFZ
standard.
(VII) Robustness
To determine the robustness of the method, the experimental conditions were purposely altered and chromatographic resolution between (S)-EFZ and (R)-EFZ was evaluated. To study the effect of flow rate on the resolution of
enantiomers, it was varied between 0.6 to 1.0 mL/min with
0.2-unit increments. Further, to examine the effect of the
organic modifier (trifluoroacetic acid) on the resolution of
enantiomers, its composition was fixed at 0.04 and 0.06% in
the mobile phase and the chromatograms were recorded. The
influence of the organic solvent, 2-propanol, in the mobile
phase on resolution was studied by varying it from -1 to +1%
and keeping other mobile phase components constant. The
% RSD value (n=3) for the resolution between (S)-EFZ and
(R)-EFZ was calculated.
(VIII) Solution Stability
Standard solutions of (S)-EFZ and (R)-EFZ were
prepared in the mobile phase at analyte concentration levels.
Each standard solution was analyzed immediately after
preparation and divided into two parts. One part was stored
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I. Method Development
To achieve separation between the enantiomers of EFZ,
immobilized polysaccharide chiral stationary phases (CSPs)
containing cellulose and amylose derivatives were examined
with suitable mobile phase compositions. The chiral discrimination of enantiomers occurs when they bind to the stationary
phase forming transient diastereomeric complexes. The most
important interactions between the analyte and CSP include
hydrogen bonding, dipole-dipole interactions and pi-pi interactions, together with the rigid structure (cellulose-based
CSP; 1, 4-connected-β-D-glucose unit) or helical structure
(amylose-based CSP; 1, 4-connected-α-D-glucose unit) of
the chiral polymer bound to the support. Various combinations of n-hexane-ethanol and n-hexane-2-propanol, in the
absence and presence of TFA, were used as the mobile phases
in the initial trials. Attempts to separate the enantiomers on
amylose carbamate derivatized columns in normal phase
(Chiralcel AD and AD-H) proved futile. The enantiomers
could not be resolved satisfactorily even with the cellulose
ester derivatized columns (Chiralcel OJ and Chiralcel OB).
The separation was attempted in reversed phase using
cellulose and amylose carbamate derivatized columns
(Chiralcel OD-RH and Chiralpak AD-RH) with mobile phase
consisting of a mixture of ammonium acetate buffer (pH 6.8)
with acetonitrile or with potassium dihydrogen phosphate
buffer (pH 4.5) and acetonitrile in various ratios. No separation was achieved in reversed phase chiral stationary phases.
The enantiomers were found to be separated only on
Cellulose tris(3,5-dimethylphenyl)carbamate coated on
silica gel based CSP (Chiralcel OD-H), with mobile phase
comprising either a mixture of n-hexane, ethanol and TFA or
n-hexane, 2-propanol and TFA. Owing to the smaller particle
size of the stationary phase, the chiralcel OD-H yielded a
better separation. In the case of CSPs with carbamate derivatives, binding of solute to the CSPs was achieved through
the interactions between the solutes and the polar carbamate groups on CSPs(30). Solutes can bind to the carbamate
groups on the CSPs forming transient diastereomers through
hydrogen bonding to C=O and NH groups and also through
dipole-dipole interaction to the C=O moiety. These could
contribute to the interactions with the carbamate groups on
CSP, resulting in separation. The aromatic ring on the solute
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Figure 2. A representation of supra-molecular binding of EFZ on chiral groove of tris-(3, 5-dimethylphenyl) carbamate of cellulose unit (1,
4-connected-β-D-glucose).
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Table 1. System suitability parameters
Retention
Time (min)

USP
tailing

Resolution

USP
plate count

(S)- EFZ

7.556

1.326

Not applicable

7951

(R)- EFZ

9.223

1.359

2.921

3546

Name

1.00
0.90
0.80

Absorbance units

could provide additional stabilizing effect to the solute-CSP
complex by insertion of the aromatic portion of the solute into
the chiral cavity(31). In the present study, we too propose the
existence of this type of stabilization effect due to the presence of aromatic functionality in EFZ. The representation of
supra-molecular binding of EFZ on chiral groove of tris-(3,
5-dimethylphenyl) carbamate cellulose unit is represented in
Figure 2.
The use of 2-propanol in the mobile phase provided better
selectivity and resolution than ethanol. The addition of up to
0.05% (by volume) of TFA to the mobile phase resulted in
improved peak shapes, better resolution and shorter run times.
TFA is the simplest stable perfluorinated carboxylic
acid chemical compound. It is strong carboxylic acid due to
the influence of the electronegative tifluoromethyl group. A
majority of the enantioseparations of chiral acidic and basic
compounds on the CSP require the addition of acidic mobile
phase modifiers. TFA plays an important role in the adsorption-desorption process. Without the TFA modifier, EFZ
enantiomers peaks exhibited tailing and poor separation and
these were due to the strong interaction of EFZ with accessible silanol groups of the CSP. TFA essentially deactivated
the CSP resulting in symmetrical peaks and better resolution.
Furthermore, TFA displaced the analytes’ acidic group on
silanol sites of the CSP and suppressed the ionization of the
weakly acidic silanol groups.
The effect of temperature, flow rate and concentrations
of 2-propanol and TFA, on resolution (Rs) and retention time
(tR) were examined. The most optimum conditions were
found to be a mobile phase consisting of n-hexane, 2-propanol
and trifluoroacetic acid in the ratio of 90 : 10 : 0.05% (v/v/v)
at a flow rate of 0.8 mL/min with the column maintained at
ambient temperature. All the system suitability parameters
including resolution, tailing factor and plate counts values
were observed to be within the acceptable limits (Table 1). In
the present method, the typical retention times of (S)-EFZ and
(R)-EFZ were observed to be 7.5 and 9.2 min, respectively.

0.70

(S)-EFZ-7.553
(R)- EFZ-9.223

0.60
0.50
0.40
0.30
0.20
0.10
0.00
-0.10
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

Time (min)

Figure 3. A typical chromatogram of EFZ (racemate) using an isocratic
eluent of n-hexane: 2-propanol: TFA in 90 : 10 : 0.5% v/v for 15 min
(UV absorption at 245 nm).

A typical chromatogram of the EFZ racemate is shown in
Figure 3.
The specificity of the method was evaluated by analyzing
the pharmaceutical excipients along with the dosage form
(n = 5). The results were found to be in the range of 98.7
to 104.0% with RSD values of less than 1%. These results
revealed the specificity of the proposed method.
II. Limit of Detection (LOD) and Quantification (LOQ)
The ICH guidelines were followed to calculate the LOD
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and LOQ values. The LOD and LOQ were found to be 66
and 200 ng/mL, respectively. These results suggested that the
proposed method is sufficiently sensitive for the determination of EFZ enantiomers.

The recoveries ranged from 98.7 to 104.0% (Table 3). Large
percentage recovery values revealed that the proposed
method is accurate and could be adopted for routine qualitycontrol analysis. A typical chromatogram of the spiked standard is shown in Figure 4.

III. Precision
VI. Robustness
The precision studies for (R)-EFZ were performed at
LOQ level and at 1% of the analyte concentration. The %
RSD values at LOQ level and 1% level were found to be 2.41
and 0.75, respectively. For inter-day and intra-day precision
at 1% concentration, the % RSD values were noticed to be
1.39 and 0.54, respectively (Table 2).

In order to anticipate any problems that may arise
during the application of the method, the method parameters,
namely, flow rate, column temperature and percentage of
trifluoroacetic acid in the mobile phase were intentionally
varied and the effects were studied. The chromatographic
resolution of the (S)-EFZ and (R)-EFZ peaks was used to

IV. Linearity and Range

V. Accuracy
The recoveries were calculated from the slope and the
intercept of the calibration plot for the (R)-EFZ standard.

0.50
0.40

Absorbance units

The calibration plot revealed a linearity range of 200
- 6210 ng/mL for (R)-EFZ with a determination coefficient
value of 0.9999.

0.30
0.20

(S)-EFZ - 7.588

0.10

(R)-EFZ - 9.265

0.00
0.00

Table 2. Precision for (R)-EFZ

a

Retention time

6.00

8.00

10.00

12.00

14.00

Figure 4. A typical chromatogram of (S)-EZ spiked with 1% (w/w)
(R)-EFZ.

0.03

Peak area

2.41

Repeatability at 1% level

Table 4. Robustness of the chiral LC method

a

Retention time

USP resolution between
(S)-EFZ and (R)-EFZ

% RSD

0.6

3.0

9.4

0.02

0.8

2.9

0.54

1.0

2.5

0.01

Peak area

0.75

Intra-day precision at 1% concentration

a

Retention time
Peak area
Inter-day precision at 1% level

a

4.00

Time (min)

% RSD
Repeatability at LOQ level

2.00

a

Parameter
Flow rate (mL/min)

Column temperature (°C)

Retention time

0.43

20

3.1

Peak area

1.39

25

2.9

30

2.7

n = 6 determinations.

6.9

2-propanol percentage in mobile phase
Table 3. Accuracy data for (R)-EFZ
Amount spiked
(µg/mL)

9

3.0

10

2.9

11

2.7

Amount recovered
(µg/mL)

Percentage Recovery

0.25

0.26 ± 0.009

104.0

3.19

3.15 ± 0.03

98.7

0.04

3.0

4.05

4.01 ± 0.07

99.0

0.05

2.9

4.96

4.99 ± 0.02

100.6

0.06

2.9

n=3
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5.3

Trifluoroacetic acid percentage in mobile phase
2.0

n=3
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evaluate the robustness of the method under modified conditions. Sufficient resolution for (S)-EFZ and (R)-EFZ was
obtained under all the tested separation conditions, thereby
demonstrating sufficient robustness of the developed method
(Table 4). The % RSD values for resolution between (S)-EFZ
and (R)-EFZ were found to be less than 10 in the altered
chromatographic conditions. Hence, it was concluded that
the proposed method had good robustness for the analysis of
EFZ in bulk sample or tablets.
VII. Solution Stability
No change in either the chemical or enantiomeric purity
was observed. The peak areas for each isomer after 24 h
did not show any significant change compared to those in
the initial analysis step (Table 5). This indicated that both
the isomers were stable in the mobile phase for at least 24 h
when stored, either between 2 - 8°C or at bench top. A typical
chromatogram of the (R)-EFZ standard is shown in Figure 5.

Table 5. Solution stability and mobile phase stability results of EFZChiral LC method
% (R)-EFZ
(solution stability)

% (R)-EFZ
(mobile phase stability)

Initial

0.15

0.15

6

0.16

0.14

12

0.15

0.14

18

0.14

0.15

24

0.15

0.15

Interval (h)

Table 6. Analysis of EFZ in pharmaceutical formulations
Formulation Labeled (mg) Found*( mg)
SUSTIVA®

5

0.61

10

9.91

0.69

99.1

15

15.03

0.54

100.2

EFAVIR®

VIII. Chiral Analysis of Bulk Drug and Formulations
Various batches of bulk drug samples and pharmaceutical formulations were analyzed in triplicate. The results
showed consistency between determinations with low %
RSD values as shown in Table 6.

% RSD % Recovery*

5.06

101.2

5

5.09

0.86

101.8

10

9.96

0.71

99.6

15

15.06

0.64

100.4

*Average of nine determinations.

0.50
0.45
0.40

A chiral HPLC method for the separation of EFZ enantiomers was developed and validated. The chiral separation was achieved using a cellulose carbamate derivatized
column (Chiralcel OD-H). The proposed method is simple,
accurate and precise. The practical applicability of this
method was tested by analyzing various batches of the
bulk drug sample and formulations. ICH guidelines were
followed throughout the study for method validation. In
view of this, the proposed method could be adopted for
quality control and routine analysis.

Absorbance units

CONCLUSIONS

0.35
0.30
0.25
0.20

(R)-EFZ - 9.235

0.15
0.10
0.05

(S)-EFZ - 7.541

0.00
-0.05
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

Time (min)
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